$1.65 +0.08 (5.10%) Arqule Inc - NASDAQ

Sep. 23, 2016 | 04:00 PM
Last Trade: 1.65
Trade Time: Sep 23 04:00 PM Eastern Daylight Time
Change: +0.08 (5.10%)
Prev Close: 1.57
Open: 1.55
Bid: 1.60
Ask: 1.64
  1. No results found.
  1. Benzinga's Top Upgrades

    Benzinga | Dec. 21, 2015 | 09:53AM EST
  2. ArQule Presents Results From Phase 1b Expansion Study of ARQ 092 at the 2015 European Cancer Conference

    Benzinga | Sep. 28, 2015 | 07:33AM EST
  3. ArQule Presents Additional Clinical Biomarker Data From Phase 2 Study of Tivantinib in Hepatocellular Carcinoma at International Liver Cancer Association Conference

    Benzinga | Sep. 8, 2015 | 07:30AM EST
  4. Jean-Marie Eveillard Adds to Stake in Arqule Inc.

    GuruFocus | May. 4, 2015 | 00:59AM EST
  5. Morning Market Movers

    Benzinga | Nov. 10, 2014 | 09:43AM EST
  6. Stocks Hitting 52-Week Lows

    Benzinga | Apr. 14, 2014 | 10:30AM EST
  7. Earnings Scheduled For March 5, 2014

    Benzinga | Mar. 5, 2014 | 04:41AM EST
  8. Benzinga's Top #PreMarket Gainers

    Benzinga | Jan. 17, 2014 | 08:10AM EST
  9. Benzinga's Top Pre-Market Gainers

    Benzinga | Sep. 27, 2013 | 08:09AM EST
  10. UPDATE: Citigroup Downgrades ArQule on Increased Uncertainty Around Lead Cancer Drug Candidate

    Benzinga | Sep. 18, 2013 | 11:06AM EST
  11. Morning Market Losers

    Benzinga | Sep. 3, 2013 | 09:57AM EST
  12. Daiichi Sankyo and ArQule Announce Phase 2 Trial with Tivantinib in Colorectal Cancer Did Not Meet Primary Endpoint

    Benzinga | Jan. 11, 2013 | 00:32AM EST
  13. ArQule Inc. Reports Operating Results (10-Q)

    GuruFocus | Nov. 1, 2012 | 10:02AM EST
  14. Stocks Hitting 52-Week Lows

    Benzinga | Oct. 2, 2012 | 04:53AM EST
  15. Morning Market Losers

    Benzinga | Oct. 2, 2012 | 04:16AM EST
Trading Center